Oncolytic viruses: adenoviruses

Tumor-selectively replicating (oncolytic) viruses are promising tools for therapy of solid cancers and have been initially developed to achieve potent tumor lysis with acceptable side effects on healthy tissue. However, in recent years, oncolytic viruses have been recognized as therapeutic vehicles...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Virus genes Ročník 53; číslo 5; s. 700 - 706
Hlavní autoři:	Niemann, Julia, Kühnel, Florian
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	New York Springer US 01.10.2017 Springer Nature B.V
Témata:	Adenoviridae Adenoviridae - genetics Adenoviruses adverse effects Animals antineoplastic activity Biomedical and Life Sciences Biomedicine Clinical trials Cytolysis Genetic Therapy - methods Genetic Vectors - genetics Humans Immune response Immunostimulation Immunotherapy Lysis Medical Microbiology Melanoma Neoplasms - therapy Neoplasms - virology Oncolysis Oncolytic Virotherapy - methods Oncolytic Viruses - genetics Plant Sciences Virology Viruses Retargeting Checkpoint inhibition Arming Conditional replication Oncolytic virus Adenovirus
ISSN:	0920-8569, 1572-994X, 1572-994X
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Tumor-selectively replicating (oncolytic) viruses are promising tools for therapy of solid cancers and have been initially developed to achieve potent tumor lysis with acceptable side effects on healthy tissue. However, in recent years, oncolytic viruses have been recognized as therapeutic vehicles exhibiting multipronged anti-tumoral activity. Apart from direct cytolysis, stimulation of both innate and adaptive tumor-directed immune responses have been recognized as important mechanisms of oncolytic virotherapy, which were probably decisive in achieving the long-term tumor remissions that oncolytic viruses have shown in clinical trials in advanced melanoma. In this short review, we will introduce basic mechanisms of viral oncolysis and the current state of clinical development. With a focus on oncolytic adenoviruses, we will describe the efforts to restrict oncolytic virus infection to tumor tissue using conditional replication and targeted delivery. Furthermore, we will discuss ways to optimize virus-mediated immunostimulation and the potential of virotherapy as an integrative part of systemic tumor immunotherapies.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
ISSN:	0920-8569 1572-994X 1572-994X
DOI:	10.1007/s11262-017-1488-1